scholarly journals Serum albumin is a strong predictor of death in chronic dialysis patients

1993 ◽  
Vol 44 (1) ◽  
pp. 115-119 ◽  
Author(s):  
Kunitoshi Iseki ◽  
Nobuyuki Kawazoe ◽  
Koshiro Fukiyama
1993 ◽  
Vol 4 (5) ◽  
pp. 1184-1191
Author(s):  
M V Rocco ◽  
J R Jordan ◽  
J M Burkart

The efficacy number has been proposed as a predictor of clinical outcome in patients on chronic ambulatory peritoneal dialysis (CAPD). The usefulness of this parameter in a large group of CAPD patients was analyzed. Forty-five patients who have received chronic CAPD therapy for at least 1 yr were included in the study. The efficacy number was compared with outcome as defined by mortality and days of hospitalization. Other demographic and laboratory parameters, including gender; race; presence of diabetes; serum albumin, serum creatinine, and BUN levels; and measures of peritoneal transport, including dialysate-to-plasma creatinine and dialysate-to-plasma urea ratios, were also assessed for their role in predicting outcome. Laboratory values were obtained at the initiation of CAPD and at 12 months after the start of CAPD. By univariate analysis, a low 12-month serum albumin level was the best predictor of mortality (P < 0.005), followed by a high 12-month efficacy number (P < 0.05). After adjusting for age and the presence of diabetes, these two variables remained the best predictors of mortality (P < 0.08 and < 0.09, respectively). A low initial serum albumin level was also a strong predictor of mortality (P < 0.09). By univariate analysis, the best predictor of hospitalization was a low serum albumin level obtained either initially or at 12 months (P < 0.005 for both time periods). After adjusting for age and the presence of diabetes, the 12-month serum albumin level remained a significant predictor of hospitalization (P < 0.03), whereas efficacy number was not a strong predictor (P = 0.27).(ABSTRACT TRUNCATED AT 250 WORDS)


2017 ◽  
Vol 68 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Andrei Niculae ◽  
Cristiana David ◽  
Razvan Florin Ion Dragomirescu ◽  
Ileana Peride ◽  
Flavia Liliana Turcu ◽  
...  

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii511-iii511
Author(s):  
Jose Tarcisio Giffoni de Carvalho ◽  
Marion Schneider ◽  
Lilian Cuppari ◽  
Caren Cristina Grabulosa ◽  
Silvia Regina Manfredi ◽  
...  

2021 ◽  
Vol 6 (4) ◽  
pp. S237
Author(s):  
J. SANTACRUZ ◽  
C. Santacruz Tipanta ◽  
A. Vasquez Pérez ◽  
P. Reinoso ◽  
S. Carlotta ◽  
...  

1998 ◽  
Vol 32 (4) ◽  
pp. 629-634 ◽  
Author(s):  
CO Stehman-Breen ◽  
S Emerson ◽  
D Gretch ◽  
RJ Johnson

The Lancet ◽  
1979 ◽  
Vol 314 (8150) ◽  
pp. 1024-1025 ◽  
Author(s):  
A. Caralps ◽  
J. Lloveras ◽  
J. Andreu ◽  
A. Brulles ◽  
J. Masramon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document